

Figure 1A

Fusion Protein Platform | 3 Touchpoints, Many Options




Figure 1B

# Fusion Protein Platform | 3 Touchpoints, Many Options





Figure 2



### Figure 3




Figure 4





Figure 5

TriTouch 4101 | One Fusion Protein, Multiple Cellular Targets



### Figure 6

**TriTouch  $\Delta$ 102-105**

# Activating NK Cells via Fc $\gamma$ R11a, 4-1BB and Inhibitory Receptor

## Modulation




Figure 7





Figure 8

***TriTouch  $\Delta 110/111$***   
*Activating TAM (M1) via  $Fc\gamma R$ , SIRP $\alpha$  and CD40 (or PD-1) Modulation*








Figure 10

hFcA/hFcB









Figure 12

Figure 13







Figure 15








Figure 18

hFcA/hTIGIT-FcB binds to cells expressing human CD155




Figure 19

hFcA/hTIGIT-FcB binds to cells expressing human CD112




Figure 20

hFcA/hCD155-FcB binds to cells expressing human TIGIT




Figure 21

hFcA/hTIGIT-FcB and hFcA/hCD155-FcB bind to cells expressing CD16 (FcγRIIIa)







Figure 22





Figures 23A-23D





Figure 24




Figure 25




Figure 26A






Figure 26B

Figure 27

